DekaBank Deutsche Girozentrale bought a new position in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 38,200 shares of the biopharmaceutical company’s stock, valued at approximately $753,000.
Other large investors have also added to or reduced their stakes in the company. Fred Alger Management Inc. acquired a new stake in Sangamo Therapeutics in the fourth quarter valued at about $148,000. Xact Kapitalforvaltning AB acquired a new stake in Sangamo Therapeutics in the fourth quarter valued at about $175,000. Chicago Equity Partners LLC acquired a new stake in Sangamo Therapeutics in the fourth quarter valued at about $192,000. Dupont Capital Management Corp acquired a new stake in Sangamo Therapeutics in the first quarter valued at about $258,000. Finally, Jefferies Group LLC acquired a new stake in Sangamo Therapeutics in the fourth quarter valued at about $295,000. 63.74% of the stock is currently owned by institutional investors and hedge funds.
Sangamo Therapeutics stock opened at $15.95 on Monday. The company has a quick ratio of 4.78, a current ratio of 4.78 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -22.79 and a beta of 2.83. Sangamo Therapeutics Inc has a 12 month low of $6.55 and a 12 month high of $27.50.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing the consensus estimate of $0.29 by ($0.52). The firm had revenue of $12.60 million during the quarter, compared to the consensus estimate of $53.09 million. Sangamo Therapeutics had a negative net margin of 126.96% and a negative return on equity of 30.96%. Sangamo Therapeutics’s revenue for the quarter was up 270.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.23) earnings per share. research analysts anticipate that Sangamo Therapeutics Inc will post -0.54 EPS for the current year.
Several research firms recently weighed in on SGMO. BidaskClub raised Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 17th. Zacks Investment Research lowered Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 16th. ValuEngine lowered Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 8th. Jefferies Group reaffirmed a “buy” rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. Finally, Wedbush reaffirmed a “hold” rating and issued a $8.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 13th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $21.67.
In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 2,278 shares of the stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $18.30, for a total value of $41,687.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Kathy Yi sold 5,000 shares of the stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $25.56, for a total value of $127,800.00. Following the completion of the transaction, the chief financial officer now owns 12,250 shares of the company’s stock, valued at $313,110. The disclosure for this sale can be found here. Insiders sold 81,539 shares of company stock valued at $1,734,825 over the last quarter. Corporate insiders own 1.20% of the company’s stock.
Sangamo Therapeutics Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.